Article Text

Download PDFPDF
Association of the ARLTS1 Variants With Familial Ovarian Cancer Risk in China
  1. Xiao-Yun Yang, MD*,
  2. Hai Yu, MD§,
  3. Ming-Rong Xi, MD*,
  4. Kai-Xuan Yang, MD,
  5. Xiao-Ling Pan, MD*,
  6. Ming Hu, MD and
  7. Zhi-Lan Peng, MD*
  1. *Department of Obstetrics and Gynecology,
  2. Department of Pathology, and
  3. Research Center, West China Second University Hospital, Sichuan University; and
  4. §Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu, People's Republic of China.
  1. Address correspondence and reprint requests to Zhi-Lan Peng, MD, Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu 610041, Sichuan, People's Republic of China. E-mail: zhilanpeng{at}


ARLTS1 has been identified in chromosome 13q14 as a tumor suppressor gene of the adenosine diphosphate-ribosylation factor family with pro-apoptotic characteristics. The ARLTS1 mutation Trp149Stop and Cys148Arg have been shown to be associated with familial cancers, but limited information is available regarding the impact of ARLTS1 variants on familial ovarian cancer (OC). The aim of this study was to evaluate the ARLTS1 genetic variants associated with familial OC risk in China. We genotyped 85 OC patients with family ovarian/breast history, 80 sporadic OC patients, and 120 controls from general population by denaturing high-performance liquid chromatography screening analysis followed by direct sequencing of the conspicuous polymerase chain reaction products. ARLTS1 Cys148Arg revealed a significant association with an increased risk of familial OC compared with both sporadic cases and controls in a dose-dependent manner (P = 0.0031 and 0.012, respectively). In the clinical-pathological study, our results support previous data in demonstrating that familial OC was associated with younger age at diagnosis (49.7 years vs 53.3 years; P = 0.014), higher proportion of tumors of advanced stages (81.2% vs 67.5%; P = 0.033), and higher rates of serous adenocarcinomas (76.4% vs 53.8%; P = 0.028) compared with sporadic OC cases. To investigate the association between genetic variants of ARLTS1 and the clinical-pathological characteristics of familial OC, we identified a significantly higher proportion of serous adenocarcinoma (55/67, 82.1%) and higher rates of advanced stage tumors (88.1% vs 55.6%; P = 0.004) in ARLTS1 Cys148Arg carriers. We showed a significantly increased risk of familial OC for ARLTS1 Cys148Arg variant, which indicate that ARLTS1 may play a role in familial OC.

  • Family history
  • Ovarian cancer
  • ARLTS1 gene
  • Tumor suppressor
  • Polymorphism

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.